Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial

British Journal of Dermatology

Volumn 162, Issue 3, 2010, Pages 661-668

  Schmitt, J ^a   Schakel K ^a   Folster Holst R ^b   Bauer, A ^a   Oertel, R ^a   Augustin, M ^c   Aberer, W ^d   Luger, T ^e   Meurer, M ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Adults; Atopic dermatitis; Ciclosporin; Prednisolone; Randomized controlled trial

Indexed keywords

ANTIHISTAMINIC AGENT; CYCLOSPORIN A; EMOLLIENT AGENT; PLACEBO; PREDNISOLONE; STEROID; ANTIINFLAMMATORY AGENT; CYCLOSPORIN; DERMATOLOGICAL AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ECZEMA; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; SKIN INFECTION; TREATMENT OUTCOME; WEIGHT GAIN; ADOLESCENT; STATISTICS; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; CYCLOSPORINE; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; ECZEMA; FEMALE; HUMANS; MALE; PREDNISOLONE; STATISTICS AS TOPIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 76949095922     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09561.x     Document Type: Article

References (38)

1. Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med 2005 352 : 2314 2324.
2. Laughter D, Istvan JA, Tofte SJ et al. The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol 2000 43 : 649 655.
3. Herd RM, Tidman MJ, Prescott RJ et al. Prevalence of atopic eczema in the community: the Lothian Atopic Dermatitis study. Br J Dermatol 1996 135 : 18 19.
4. Finlay AY. Quality of life in atopic dermatitis. J Am Acad Dermatol 2001 45 (Suppl. 1 S64 6.
5. Schmitt J, Meurer M, Klon M et al. Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema - a population-based study. Br J Dermatol 2007 158 : 351 359.
6. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003 112 (Suppl. 6 S118 27.
7. Schmitt J, Romanos M, Schmitt NM et al. Atopic eczema and attention-deficit/hyperactivity disorder in a population-based sample of children and adolescents. JAMA 2009 301 : 724 726.
8. Schmitt J, Romanos M, Pfennig A et al. Psychiatric comorbidity in adult eczema. Br J Dermatol 2009 161 : 878 883.
9. Fivenson D, Arnold RJ, Kaniecki DJ et al. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. J Manag Care Pharm 2002 8 : 333 342.
10. Herd RM, Tidman MJ, Prescott RJ et al. The cost of atopic eczema. Br J Dermatol 1996 135 : 20 3.
11. Schmitt J, Schmitt NM, Kirch W et al. Significance of atopic dermatitis in outpatient medical care. Analysis of health care data from Saxony. Hautarzt 2009 60 : 320 327.
12. Schmitt J, Meurer M, Schwanebeck U et al. Treatment following an evidence-based algorithm versus individualised symptom-oriented treatment for atopic eczema. A randomised controlled trial. Dermatology 2008 217 : 299 308.
13. Ellis C, Luger T, Abeck D et al. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol 2003 148 (Suppl. 63 3 10.
14. Schmitt J, Schmitt NM, Kirch W, Meurer M. Outpatient care and medical treatment of children and adults with atopic eczema. J Dtsch Dermatol Ges 2009 7 : 345 351.
15. Schmitt J, Schäkel K, Schmitt N et al. Systemic treatment of severe atopic eczema: a systematic review. Acta Derm Venereol (Stockh) 2007 87 : 100 111.
16. Schmitt J, Schmitt NM, Meurer M. Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007 21 : 606 619.
17. Williams HC, Burney PG, Hay RJ et al. The U.K. Working Party's diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 1994 131 : 383 396.
18. Williams HC, Burney PG, Pembroke AC, Hay RJ. Validation of the U.K. diagnostic criteria for atopic dermatitis in a population setting. U.K. Diagnostic Criteria for Atopic Dermatitis Working Party. Br J Dermatol 1996 135 : 12 17.
19. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993 186 : 23 31.
20. Kunz B, Oranje AP, Labreze L et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997 195 : 10 19.
21. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 19 : 210 216.
22. Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004 9 : 169 180.
23. Werfel T, Aberer W, Augustin M et al. Neurodermitis. Leitlinien der Deutschen Dermatologischen Gesellschaft (DDG) und des Berufsverbandes Deutscher Dermatologen (BVDD). 2008. Available at: http://www.uni-duesseldorf.de/WWW/AWMF/ ll/013-027.htm (last accessed 20 October 2009).
24. Williams H, Thomas K, Smethurst D et al. Atopic eczema. In : Evidence Based Dermatology (Williams H, Bigby M, Diepgen T et al., eds 1st edn. London : BMJ Books, 2003 144 218.
25. Nieder R Glukokortikoide. In : Therapeutische Verfahren in der Dermatologie (Korting HC, Sterry W, eds 1st edn. Berlin : Blackwell Wissenschafts Verlag, 2001 411 421.
26. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003 361 : 151 160. (Pubitemid 36092023)
27. Leung D, Eichenfield LF, Boguniewicz M. Atopic dermatitis. In : Fitzpatrick's Dermatology in General Medicine (Freedberg KA, Eisen AZ, Wolff K et al., eds 6th edn. New York : McGraw-Hill, 2003 1180 1194.
28. Harper JI, Ahmed I, Barclay G et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000 142 : 52 8.
29. Khilij FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality Index Scores. Br J Dermatol 2002 147 (Suppl. 62 50.
30. Zurbriggen B, Wuthrich B, Cachelin AB et al. Comparison of two formulations of cyclosporin A in the treatment of severe atopic dermatitis. A double-blind, single-centre, cross-over pilot study. Dermatology 1999 198 : 56 60.
31. van Joost T, Heule F, Korstanje M et al. Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br J Dermatol 1994 130 : 634 640. (Pubitemid 24204701)
32. Granlund H, Erkko P, Sinisalo M et al. Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy. Br J Dermatol 1995 132 : 106 112.
33. Schmitt J, Langan SM, Williams HC. What are the best outcome measurements for atopic eczema? - A systematic review. J Allergy Clin Immunol 2007 120 : 1389 1398.
34. Brenninkmeijer EE, Schram ME, Leeflang MM et al. Diagnostic criteria for atopic dermatitis: a systematic review. Br J Dermatol 2008 158 : 754 765.
35. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 2006 367 : 839 846.
36. Berth-Jones J, Takwale A, Tan E et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002 147 : 324 330.
37. Hanifin JM, Schneider LC, Leung DY et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993 28 : 189 197.
38. Neuber K, Schwartz I, Itschert G et al. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol 2000 143 : 385 391.